JP6073038B2 - 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用 - Google Patents

安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用 Download PDF

Info

Publication number
JP6073038B2
JP6073038B2 JP2015528372A JP2015528372A JP6073038B2 JP 6073038 B2 JP6073038 B2 JP 6073038B2 JP 2015528372 A JP2015528372 A JP 2015528372A JP 2015528372 A JP2015528372 A JP 2015528372A JP 6073038 B2 JP6073038 B2 JP 6073038B2
Authority
JP
Japan
Prior art keywords
protein
amino acid
acid sequence
seq
library
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015528372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531597A5 (https=
JP2015531597A (ja
Inventor
ヒュン−クォン リム，
ヒュン−クォン リム，
サン グン キム，
サン グン キム，
ヨン ソブ パク，
ヨン ソブ パク，
ヒョ ジュン ナム，
ヒョ ジュン ナム，
ドン−シク キム，
ドン−シク キム，
ジェ チャン パク，
ジェ チャン パク，
ヨプ ユン，
ヨプ ユン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Institute for Biomedical Research
Original Assignee
Mogam Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Institute for Biomedical Research filed Critical Mogam Institute for Biomedical Research
Publication of JP2015531597A publication Critical patent/JP2015531597A/ja
Publication of JP2015531597A5 publication Critical patent/JP2015531597A5/ja
Application granted granted Critical
Publication of JP6073038B2 publication Critical patent/JP6073038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015528372A 2012-08-22 2012-08-22 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用 Active JP6073038B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2012/006680 WO2014030780A1 (en) 2012-08-22 2012-08-22 Screening and engineering method of super-stable immunoglobulin variable domains and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016154209A Division JP6293829B2 (ja) 2016-08-05 2016-08-05 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用

Publications (3)

Publication Number Publication Date
JP2015531597A JP2015531597A (ja) 2015-11-05
JP2015531597A5 JP2015531597A5 (https=) 2016-09-29
JP6073038B2 true JP6073038B2 (ja) 2017-02-01

Family

ID=50150075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015528372A Active JP6073038B2 (ja) 2012-08-22 2012-08-22 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用

Country Status (6)

Country Link
US (1) US10078085B2 (https=)
EP (2) EP3165535B1 (https=)
JP (1) JP6073038B2 (https=)
KR (2) KR101796689B1 (https=)
CN (3) CN113234142B (https=)
WO (1) WO2014030780A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014030780A1 (en) * 2012-08-22 2014-02-27 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
GB201419899D0 (en) 2014-11-07 2014-12-24 Univ Kent Canterbury Biopharmaceutical production method
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
KR101692629B1 (ko) * 2015-07-14 2017-01-03 계명대학교 산학협력단 매시브 플래카드 제어 장치 및 그 방법
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
AU2017259821B2 (en) * 2016-05-04 2024-07-18 Abilita Bio, Inc. Methods and platform for preparing multispanning membrane proteins
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
CN111201243B (zh) 2017-09-29 2023-08-11 财团法人牧岩生命科学研究所 对bcma具有高亲和力的抗bcma抗体和包含其的用于治疗癌症的药物组合物
KR102115300B1 (ko) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
CN108893487A (zh) * 2018-07-19 2018-11-27 中国农业科学院北京畜牧兽医研究所 一种含有C-Myc蛋白融合标签的植物表达质粒载体及其载体的构建方法
WO2020127993A1 (en) * 2018-12-21 2020-06-25 Vib Vzw Fusion protein with a toxin and scaffold protein

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960007784B1 (ko) 1993-07-02 1996-06-12 포항종합제철 주식회사 일산화탄소(co)가스 센서 및 그 제조방법
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2002531113A (ja) * 1998-12-10 2002-09-24 ワシントン大学 蛋白質の形質導入システムおよびその使用法
WO2001018058A2 (en) * 1999-09-07 2001-03-15 Viventia Biotech Inc. Enhanced phage display library of human vh fragments and methods for producing same
US8372954B2 (en) * 2000-12-22 2013-02-12 National Research Council Of Canada Phage display libraries of human VH fragments
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
JP2006508638A (ja) * 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
JP2006517789A (ja) * 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
WO2006026759A2 (en) 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
US20070026012A1 (en) * 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
EP2360473A1 (en) * 2005-08-22 2011-08-24 Cornell Research Foundation Compositions and methods for analyzing protein interactions
EP2441838A3 (en) 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
EP1981979A4 (en) 2006-01-31 2009-07-29 Republic Of Korea Republic Of PROCESS FOR PRODUCING A SOLUBLE NATIVE FORM OF RECOMBINANT PROTEIN USING THE SIGNAL SEQUENCE AND A SECRETION ENHANCING AGENT
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
CN101720368A (zh) * 2007-03-09 2010-06-02 中国抗体制药有限公司 储备多样性最大化的功能性人化抗体文库之构建及应用
KR20100024943A (ko) * 2007-06-18 2010-03-08 다니스코 유에스 인크. 원핵생물에서의 단백질 생성을 위한 ｔａｔ 신호 펩타이드
WO2009089295A2 (en) * 2008-01-07 2009-07-16 Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Anti-hiv domain antibodies and method of making and using same
JP6093715B2 (ja) 2011-01-28 2017-03-08 ナショナル リサーチ カウンシル オブ カナダ 免疫グロブリンドメインの工学的作製
WO2014030780A1 (en) * 2012-08-22 2014-02-27 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses

Also Published As

Publication number Publication date
CN106986934A (zh) 2017-07-28
WO2014030780A1 (en) 2014-02-27
KR101796689B1 (ko) 2017-11-10
KR20150032337A (ko) 2015-03-25
CN113234142B (zh) 2024-03-05
CN104769113B (zh) 2017-10-31
US10078085B2 (en) 2018-09-18
KR20160072272A (ko) 2016-06-22
EP3165535A1 (en) 2017-05-10
CN106986934B (zh) 2021-09-14
JP2015531597A (ja) 2015-11-05
EP2888367B1 (en) 2020-04-29
EP3165535B1 (en) 2019-05-15
EP2888367A1 (en) 2015-07-01
KR101732552B1 (ko) 2017-05-08
CN104769113A (zh) 2015-07-08
EP2888367A4 (en) 2016-04-20
US20160003844A1 (en) 2016-01-07
CN113234142A (zh) 2021-08-10

Similar Documents

Publication Publication Date Title
JP6073038B2 (ja) 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
JP2015531597A5 (https=)
JP6253986B2 (ja) コレクション及びその使用方法
US20260071204A1 (en) Integrated system for library construction, affinity binder screening and expression thereof
CN107513104A (zh) 免疫球蛋白结构域的工程改造
JP2021531822A (ja) 抗体の開発可能性が最大化された抗体ライブラリー
US20250020659A1 (en) Single domain antibody libraries with maximized antibody developability characteristics
KR102216032B1 (ko) 합성 항체 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
JP6293829B2 (ja) 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
HK40051447A (en) Screening and engineering method of super-stable immunoglobulin variable domains and their uses
Leow et al. Monoclonal IgY antibodies
CN119591716B (zh) 一种结合人CD8β的VHH及其应用
US20250019460A1 (en) Peptide having framework sequence for random region placement and peptide library composed of said peptide
HK40051447B (zh) 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
WO2025154793A1 (ja) 多重特異性抗体の製造に使用するための共通のｌ鎖を同定する方法
JP2023552397A (ja) 可変重鎖のみのライブラリ、その調製方法、及びその使用
Seo Development of high throughput screening systems for the efficient production of antibody fragments in Escherichia coli
Tiller Synthetic Antibodies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160607

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170103

R150 Certificate of patent or registration of utility model

Ref document number: 6073038

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250